The “Chronic Fatigue Syndrome Therapeutics Market by Product (Pain relievers and NSAIDs, Antidepressant and antipsychotic drugs, and Antimicrobial and immunomodulatory drugs) and Geography (North America, Europe, Asia, and Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the chronic fatigue syndrome therapeutics market size between 2021 and 2026 is USD 51.84 million. To get the exact CAGR and the Y-O-Y growth rate, Request a Sample Report
- Market Driver: The increasing use of off-label pharmacological treatment for CFS is driving the growth of the market. Graded exercise and CBT are considered the first-line treatment for CFS. Patients with CFS are more likely to consult a complementary or alternative healthcare provider instead of a physiotherapist or psychologist for advice and support. As there are no approved drugs for the treatment of CFS, a wide range of pain relievers, antidepressants, antibiotics, and immunomodulators are being prescribed off-label for improving symptoms.
- Market Challenge: The confirmation of specific diagnostic tests for confirmation of CFS is challenging the growth of the market. CFS can be a symptom of other medical conditions, such as chronic mononucleosis, fibromyalgia, neurological conditions, Lyme disease, and sensitivity to certain chemicals. It can also be a symptom in many treatable diseases such as depression, cancer, subacute or chronic infections, psychosomatic diseases, and malingering. Thus, more education is required about CFS among healthcare professionals. Such factors may challenge the market growth in the forecast years.
North America will be the leading region with 42% of the market’s growth during the forecast period. The growth is attributed to factors such as high per capita pharmaceutical expenditure, access to advanced healthcare, the strong market presence of leading vendors, and the increasing awareness about CFS. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the chronic fatigue syndrome therapeutics market in North America. The growing prevalence of CFS in the US is also driving the growth of the regional market. According to the Centers for Disease Control (CDC), the prevalence of CFS in the US is around 11.5%.
The pain relievers and NSAIDs segment will have significant market share growth during the forecast period. Pain relievers are the most commonly used drugs, as they can help in relieving pain and reducing inflammation. Ibuprofen is the most commonly used NSAID. Body pain is the most frequently reported reason for the use of NSAIDs in CFS patients. Arthritis and headache are the second-most and the third-most frequently reported reasons, respectively.
- AIM ImmunoTech Inc.
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Bionpharma Inc.
- Cadila Pharmaceuticals Ltd.
- Hikma Pharmaceuticals Plc
- Lupin Ltd.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Narcolepsy Drugs Market by Type and Geography – Forecast and Analysis 2022-2026
Mental Health Market by Service and Geography – Forecast and Analysis 2022-2026
